Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 4/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681167 | 0.95 | HRH3 (0.49) | HRH3SLC6A4NMT1ITGB3ITGA2B | |
| SCHEMBL4708456 | 0.89 | HRH3 (0.51) | HRH3SLC6A4ITGB3ITGA2BGBA1 | |
| SCHEMBL17064317 | 0.87 | HRH1 (0.48) | HRH3HRH1HRH4LOXL2 | |
| SCHEMBL10774121 | 0.85 | HRH3 (0.43) | HRH3NMT1ITGB3ITGA2BHRH1 | |
| SCHEMBL82734 | 0.82 | GBA1 (0.61) | HRH3SLC6A4ITGB3ITGA2BGBA1 | |
| SCHEMBL5048693 | 0.81 | HRH3 (0.41) | HRH3SLC6A4NMT1ITGB3ITGA2B | |
| SCHEMBL4334188 | 0.81 | CHRM2 (0.53) | HRH3SLC6A4HRH1GBA1HRH4 | |
| Hydrochloric Acid SCHEMBL7669421 | 0.81 | GBA1 (0.59) | HRH3SLC6A4ITGB3ITGA2BGBA1 | |
| SCHEMBL5749309 | 0.80 | HTR2C (0.51) | HRH3SLC6A4NMT1ITGB3ITGA2B | |
| SCHEMBL5048704 | 0.80 | CYP2D6 (0.37) | HRH3HRH1GBA1HRH4LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | HRH3 262/4885SLC6A4 248/4885NMT1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.